Evidence map›Paper›PMID 37726213›Full record

ArticleACS chemical neuroscience2023

Virtual Screening-Accelerated Discovery of a Phosphodiesterase 9 Inhibitor with Neuroprotective Effects in the Kainate Toxicity In Vitro Model.

Elisa Landucci, Giovanni Ribaudo, Margrate Anyanwu, Erika Oselladore, Matteo Giannangeli, Costanza Mazzantini, Daniele Lana, Maria Grazia Giovannini, Maurizio Memo, Domenico E Pellegrini-Giampietro and 1 more

Open access · hybridAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elisa LanducciDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze 50139, Italy.
Giovanni RibaudoDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.ORCID 0000-0003-3679-5530
Margrate AnyanwuDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.
Erika OselladoreDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.ORCID 0000-0002-2546-1343
Matteo GiannangeliDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.
Costanza MazzantiniDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze 50139, Italy.
Daniele LanaDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze 50139, Italy.
Maria Grazia GiovanniniDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze 50139, Italy.
Maurizio MemoDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.ORCID 0000-0002-7543-0289
Domenico E Pellegrini-GiampietroDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze 50139, Italy.
Alessandra GianoncelliDepartment of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy.ORCID 0000-0002-0816-5163
University of Brescia · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the central nervous system, some specific phosphodiesterase (PDE) isoforms modulate pathways involved in neuronal plasticity. Accumulating evidence suggests that PDE9 may be a promising therapeutic target for neurodegenerative diseases. In the current study, computational techniques were used to identify a nature-inspired PDE9 inhibitor bearing the scaffold of an isoflavone, starting from a database of synthetic small molecules using a ligand-based approach. Furthermore, docking studies supported by molecular dynamics investigations allowed us to evaluate the features of the ligand-target complex. In vitro assays confirmed the computational results, showing that the selected compound inhibits the enzyme in the nanomolar range. Additionally, we evaluated the expression of gene and protein levels of PDE9 in organotypic hippocampal slices, observing an increase following exposure to kainate (KA). Importantly, the PDE9 inhibitor reduced CA3 damage induced by KA in a dose-dependent manner in organotypic hippocampal slices. Taken together, these observations strongly support the potential of the identified nature-inspired PDE9 inhibitor and suggest that such a molecule could represent a promising lead compound to develop novel therapeutic tools against neurological diseases..

Indexed as

Neuroprotective AgentsPhosphodiesterase Inhibitors3',5'-Cyclic-AMP PhosphodiesterasesHippocampusKainic AcidLigandsPhosphoric Diester Hydrolases3',5'-Cyclic-AMP PhosphodiesterasesKainic AcidLigandsNeuroprotective AgentsPhosphodiesterase InhibitorsPhosphoric Diester Hydrolasesisoflavoneskainatemolecular modelingneurodegenerationorganotypic hippocampal slicesPDE9

Identifiers

PMID37726213
PMCPMC10587872
OpenAlexW4386850431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.